Atara Biotherapeutics EBITDA vs. Cash And Equivalents
| ATRA Stock | USD 12.26 0.14 1.16% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -266 M | Current Value -252.7 M | Quarterly Volatility 124.8 M |
For Atara Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Atara Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Atara Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Atara Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Atara Biotherapeutics over time as well as its relative position and ranking within its peers.
Atara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Atara Biotherapeutics Cash And Equivalents vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Atara Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Atara Biotherapeutics value to that of its competitors to determine the firm's financial worth. Atara Biotherapeutics is rated below average in ebitda category among its peers. It is number one stock in cash and equivalents category among its peers . At present, Atara Biotherapeutics' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atara Biotherapeutics' earnings, one of the primary drivers of an investment's value.Atara Cash And Equivalents vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Atara Biotherapeutics |
| = | (266 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Atara Biotherapeutics |
| = | 331.31 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Atara Cash And Equivalents Comparison
Atara Biotherapeutics is currently under evaluation in cash and equivalents category among its peers.
Atara Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Atara Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Atara Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Atara Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Atara Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -204 K | -214.2 K | |
| Operating Income | -276 M | -262.2 M | |
| Income Before Tax | -276.1 M | -262.3 M | |
| Total Other Income Expense Net | -105 K | -99.8 K | |
| Net Loss | -276.1 M | -262.3 M | |
| Income Tax Expense | 15 K | 15.9 K | |
| Net Loss | -290.2 M | -304.8 M | |
| Non Operating Income Net Other | 60.1 M | 63.1 M | |
| Net Loss | -205.5 M | -215.7 M | |
| Interest Income | 4.8 M | 3.2 M | |
| Net Interest Income | 944 K | 896.8 K | |
| Change To Netincome | 4.1 M | 3.9 M | |
| Net Loss | (65.18) | (68.44) | |
| Income Quality | 0.70 | 0.55 | |
| Net Income Per E B T | 1.00 | 0.95 |
Atara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Atara Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Atara Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Atara Biotherapeutics' important profitability drivers and their relationship over time.
Use Atara Biotherapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atara Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atara Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Atara Biotherapeutics Pair Trading
Atara Biotherapeutics Pair Trading Analysis
The ability to find closely correlated positions to Atara Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atara Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atara Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atara Biotherapeutics to buy it.
The correlation of Atara Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atara Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atara Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atara Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Atara Biotherapeutics position
In addition to having Atara Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 195 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
To fully project Atara Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Atara Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Atara Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.